Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction

Montelukast sodium (Singulair®, Merck and Co., Inc., Whitehouse Station, NJ) is a selective and orally-active leukotriene receptor antagonist with demonstrated effectiveness for treating allergic asthma and allergic rhinitis in adults and children as young as 12 months of age for allergic asthma and 6 months of age for allergic rhinitis. It was recently approved in the US for prevention of exercise-induced bronchoconstriction in patients who are ≥ 15 years of age. This paper updates a prior review of the data on the clinical efficacy of montelukast published in this journal.